Published in JAMA · View the paper (DOI)
Elimination of cost sharing may lead to higher naloxone prescription rates among commercially insured individuals, as well as Medicare beneficiaries. The study found a positive association between the removal of out-of-pocket costs and increased naloxone dispensing.
Coverage from 2 institutions